Since the NICE guidance on topical pimecrolimus and tacrolimus was issued, following a safety review the European Medicines Evaluation Agency (EMEA) has recommended greater caution in the way these medicines are used in order to reduce potential risks of skin cancer and lymphoma as far as possible.
Patients who are using tacrolimus and pimecrolimus should not stop or modify their treatment without consulting their prescribing healthcare professional.
Further details can be found on the EMEA website.
March 2014: implementation section updated to clarify that tacrolimus and pimecrolimus are recommended as options for treating atopic eczema. Additional minor maintenance update also carried out.
March 2012: minor maintenance